| Pathway Overview | |
|---|---|
| Category | Neuroinflammation / Lipid Signaling |
| Relevance | Moderate-High |
| Therapeutic Target | COX-2, Prostaglandin Receptors, 5-LOX, SPMs |
| Evidence Level | Preclinical to Phase 2 |
| NET Score | 28/50 (56%) |
Prostaglandins and eicosanoids are bioactive lipid mediators derived from arachidonic acid that play critical roles in neuroinflammation and neuronal survival. The cyclooxygenase (COX) and lipoxygenase (LOX) pathways produce pro-inflammatory prostaglandins and leukotrienes, while specialized pro-resolving mediators (SPMs) actively promote inflammation resolution. Dysregulation of this lipid signaling network contributes to microglial activation, cytokine release, and tau pathology progression in 4R-tauopathies including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) [1].
The arachidonic acid (AA) cascade is the central pathway for eicosanoid biosynthesis:
COX-2 is an inducible enzyme expressed in neurons and microglia that converts arachidonic acid to prostaglandin H2 (PGH2), which is then converted to various prostaglandins (PGE2, PGD2, PGI2, TXA2) by tissue-specific synthases.
COX-2 upregulation in PSP:
| Agent | Mechanism | Evidence | Status |
|---|---|---|---|
| Celecoxib | COX-2 selective inhibition | Mixed results in AD | Phase 2-3 failed |
| Rofecoxib | COX-2 selective inhibition | Cardiovascular risk | Withdrawn |
| Ibuprofen | Non-selective COX | Epidemiological benefit | Over-the-counter |
| Low-dose aspirin | Irreversible COX-1 | Cardiovascular benefit | Widely used |
Clinical considerations:
Prostaglandins signal through four EP receptor subtypes (EP1-EP4) with distinct downstream effects:
| Receptor | Signaling | Neuronal Effect | Therapeutic Relevance |
|---|---|---|---|
| EP1 | Ca²⁺ mobilization | Excitotoxicity, oxidative stress | EP1 antagonists in development |
| EP2 | cAMP elevation | Anti-inflammatory (microglial M2) | EP2 agonists explored |
| EP3 | Gi signaling | Modulates neurotransmitter release | Limited therapeutic potential |
| EP4 | cAMP/PI3K | Pro-survival, neuroprotection | EP4 agonists investigated |
EP1 antagonists:
EP2/EP4 activation:
PGE2 paradox:
The 5-lipoxygenase (5-LOX) pathway produces leukotrienes that mediate neuroinflammation:
| Agent | Target | Evidence | Status |
|---|---|---|---|
| Zileuton | 5-LOX | Not studied in tauopathy | Available for asthma |
| Montelukast | CysLT1 | Memory improvement in models | Approved for allergy |
| BLT1 antagonists | BLT1 | Preclinical | Development phase |
Clinical considerations:
SPMs are lipid mediators derived from omega-3 fatty acids (EPA and DHA) that actively resolve inflammation:
Resolvins (RvD1, RvE1):
Protectins (PD1/neuroprotectin D1):
Maresins (MaR1):
Studies demonstrate reduced SPM levels in cerebrospinal fluid of PSP patients compared to healthy controls [5]. This deficiency may contribute to chronic neuroinflammation and disease progression.
| Approach | Mechanism | Evidence | Status |
|---|---|---|---|
| High-dose omega-3 | Increase endogenous SPM | Safe; may help | Clinical use |
| SPM analogs | Direct SPM receptor agonists | Preclinical | Development |
| Aspirin-triggered SPM | Acetylated COX-2 generates SPM | Preclinical | Research phase |
Baseline evaluation:
Laboratory monitoring:
| Priority | Intervention | Dose | Rationale | Evidence Level |
|---|---|---|---|---|
| High | Omega-3 (EPA+DHA) | EPA 2-3g + DHA 1-2g/day | SPM enhancement | Clinical |
| Medium | Low-dose aspirin | 81mg daily | COX modulation | Epidemiological |
| Medium | Dietary modification | 2x fatty fish/week | SPM precursors | Clinical |
| Low | Targeted inhibitors | Per trials | Mechanism-specific | Preclinical |
| Medication | Interaction | Management |
|---|---|---|
| Levodopa | No direct interaction | Monitor for reduced efficacy with high-dose omega-3 |
| Rasagiline | No direct interaction | Safe to combine with omega-3 supplementation |
| Anticoagulants | Increased bleeding risk | Avoid NSAIDs; monitor aspirin |
| SSRIs | Serotonin syndrome (theoretical with NSAIDs) | Monitor |
| Agent | Target | Trial | Phase | Status |
|---|---|---|---|---|
| NCT01255540 | Ibuprofen | AD | Phase 3 | Completed |
| NCT01034368 | Celecoxib | AD | Phase 3 | Completed |
| NCT02049333 | N/A | Omega-3 in PSP | Phase 2 | Completed |
| Component | Relevance | Evidence | Readiness | Score |
|---|---|---|---|---|
| COX-2 inhibition | Moderate | Mixed | Available | 6/10 |
| EP receptor modulation | Low | Preclinical | Research | 4/10 |
| 5-LOX inhibition | Low | Limited | Available | 4/10 |
| SPM enhancement | High | Emerging | Safe | 8/10 |
| Combined approach | Moderate | Preclinical | Development | 6/10 |
Total NET Score: 28/50 (56%) — Moderate relevance with emerging evidence for omega-3/SPM pathway